# Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

> **NCT03561584** · PHASE2 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 32 (actual)

## Conditions studied

- Primary Sclerosing Cholangitis

## Interventions

- **DRUG:** Sulfasalazine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03561584
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-01
- **Primary completion:** 2026-03-03
- **Final completion:** 2026-03-03
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03561584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03561584, "Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03561584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*